Micro-invasive pancreaticoduodenectomy will be a promising treatment option for distal cholangiocarcinoma  

作　　者：Han-Xuan Wang Zu-Yu Wang Ren Lang Qiang He Shao-Cheng Lyu 

机构地区：[1]Department of Hepatobiliary and Pancreaticosplenic Surgery,Beijing Chaoyang Hospital,Capital Medical University,Beijing,China

出　　处：《Hepatobiliary Surgery and Nutrition》2024年第5期841-844,共4页肝胆外科与营养（英文）

摘　　要：Cholangiocarcinoma is a malignancy derived from biliary epithelial cells,a relatively rare but highly malignant type of malignancy.Cholangiocarcinoma located below the convergence of gallbladder duct and common hepatic duct is defined as distal cholangiocarcinoma(dCCA),accounting for 20-30%of total cholangiocarcinoma.In spite of the highly developed adjuvant therapy,surgical treatment remains the core in dCCA treatment,and radical pancreaticoduodenectomy is still the only potential cure for dCCA.However,the overall prognosis of dCCA after radical surgery is still unsatisfying,with a post-operative 5-year survival rate less than 40%.

关 键 词：Distal cholangiocarcinoma(dCCA) minimally invasive pancreaticoduodenectomy(MIPD) prognosis 

分 类 号：R735.8[医药卫生—肿瘤]